Projecten per jaar
Vingerafdruk
Verdiep u in de onderzoeksgebieden waarop Gil Awada actief is. Deze onderwerplabels komen uit het werk van deze persoon. Samen vormen ze een unieke vingerafdruk.
- 1 Soortgelijke profielen
Samenwerkingen en hoofdonderzoeksgebieden uit de afgelopen vijf jaar
Recente externe samenwerking op landen-/regioniveau. Duik in de details door op de stippen te klikken of
Projecten
- 1 Afgelopen
Onderzoeksoutput
-
Analysis of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: a case series
Dirven, I., Hautman, R. M. A., Awada, G., Tijtgat, J., Vounckx, M., Vanbinst, A. & Neyns, B., 21 apr 2023, (Unpublished).Onderzoeksoutput: Other
-
Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study
Fasolino, G., Awada, G., Moschetta, L., Koulalis, J. S., Neyns, B., Verhelst, B., Van Elderen, P., Nelis, P., de Lichtbuer, P. C., Cools, W. & Ten Tusscher, M., 3 feb 2023, In: Journal of clinical medicine. 12, 3, 1214.Onderzoeksoutput: Article › peer review
Open AccessBestand2 Downloads (Pure) -
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors
Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Kruse, V. & Neyns, B., 1 jun 2022, In: Melanoma Research. 32, 3, blz. 183-191 9 blz.Onderzoeksoutput: Article › peer review
6 Citaten (Scopus) -
Anti-PD-1: When to Stop Treatment
Jansen, Y., van der Veldt, A. A. M., Awada, G. & Neyns, B., jul 2022, In: Current oncology reports. 24, 7, blz. 905-915 11 blz.Onderzoeksoutput: Scientific review › peer review
Open Access6 Citaten (Scopus) -
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB)
Schwarze, J. K., Geens, W., Tijtgat, J., Awada, G., Seynaeve, L., Vanbinst, A-M., Everaert, H., Michotte, A., Bruneau, M., Van Riet, I., Tuyaerts, S., Duerinck, J. & Neyns, B., 1 jun 2022, In: Journal of Clinical Oncology. 40, 16, 2033.Onderzoeksoutput: Meeting abstract (Journal)
Open Access
Prijzen
-
Best Poster Award
Awada, Gil (Recipient), Özdemir, Ibrahim (Recipient), Schwarze, Julia Katharina (Recipient), Daeninck, Emma (Recipient), Gondry, Odrade (Recipient), Jansen, Y. (Recipient), Seremet, T. (Recipient), Keyaerts, Marleen (Recipient), Everaert, Hendrik (Recipient) & Neyns, Bart (Recipient), 15 dec 2018
Prijs: Prize (including medals and awards)
-
Prognostic value of 0-(2-[18F]-fluoroethyl)-L-tyrosine PET in patients with recurrent glioblastoma.
Wietse Geens (Speaker), Stephanie Du Four (Contributor), S VAN LAERE (Contributor), Julia Katharina Schwarze (Contributor), Gil Awada (Contributor), Michaël Bruneau (Contributor), Jens Tijtgat (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 mrt 2022Activiteit: Talk or presentation at a conference
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor) & Johnny Duerinck (Contributor)
26 mrt 2022Activiteit: Talk or presentation at a conference
-
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
Wietse Geens (Speaker), Julia Katharina Schwarze (Contributor), Cleo Bertels (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), F Vaeyens (Contributor), Louise Cras (Contributor), Anne Vanbinst (Contributor), Hendrik Everaert (Contributor), Alex Michotte (Contributor), Toon Janssen (Contributor), Ben Caljon (Contributor), Thomas Cauwenbergh (Contributor), Michaël Bruneau (Contributor), Ramses Forsyth (Contributor) & Bart Neyns (Contributor)
26 mrt 2022Activiteit: Talk or presentation at a conference
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor) & Bart Neyns (Contributor)
17 sep 2021Activiteit: Talk or presentation at a conference
-
Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): a multi-cohort adaptive phase I clinical trial
Julia Katharina Schwarze (Speaker), Wietse Geens (Contributor), Jens Tijtgat (Contributor), Gil Awada (Contributor), Anne-Marie Van Binst (Contributor), Hendrik Everaert (Contributor), Laura Seynaeve (Contributor), Alex Michotte (Contributor), Michaël Bruneau (Contributor), I VAN RIET (Contributor), Sandra Tuyaerts (Contributor), Johnny Duerinck (Contributor) & Bart Neyns (Contributor)
16 sep 2021 → 21 sep 2021Activiteit: Talk or presentation at a conference
Scriptie
-
Expanding the application of targeted therapies and immune checkpoint inhibitors in advanced melanoma and recurrent glioblastoma
Auteur: Awada, G., Neyns, B., Hes, F. J., Flaherty, K., Del Marmol, V., Engels, B., De Haar-Holleman, A. & Schots, R., 18 jun 2021Begeleider: Neyns, B. (Promotor), Flaherty, K. (Externe persoon) (Jury), Del Marmol, V. (Externe persoon) (Jury), Hes, F. J. (Jury), Engels, B. (Jury), De Haar-Holleman, A. (Jury) & Schots, H. (Jury)
Scriptie/Masterproef: Doctoral Thesis